X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3973) 3973
deoxycytidine - analogs & derivatives (2976) 2976
index medicus (2409) 2409
oncology (2198) 2198
female (1602) 1602
gemcitabine (1576) 1576
animals (1346) 1346
deoxycytidine - administration & dosage (1270) 1270
cancer (1266) 1266
male (1255) 1255
chemotherapy (1185) 1185
deoxycytidine - pharmacology (1182) 1182
cell line, tumor (1146) 1146
middle aged (1047) 1047
antineoplastic combined chemotherapy protocols - therapeutic use (946) 946
aged (934) 934
mice (853) 853
deoxycytidine - therapeutic use (806) 806
adult (804) 804
pancreatic neoplasms - drug therapy (798) 798
pancreatic cancer (782) 782
pharmacology & pharmacy (777) 777
deoxycytidine kinase (753) 753
apoptosis (641) 641
expression (613) 613
treatment outcome (598) 598
antimetabolites, antineoplastic - pharmacology (565) 565
pancreatic neoplasms - pathology (561) 561
biochemistry & molecular biology (554) 554
research (529) 529
phosphorylation (519) 519
apoptosis - drug effects (488) 488
care and treatment (476) 476
therapy (470) 470
antimetabolites, antineoplastic - therapeutic use (441) 441
antineoplastic agents - pharmacology (433) 433
dna methylation (425) 425
deoxycytidine kinase - metabolism (423) 423
dose-response relationship, drug (416) 416
cell proliferation - drug effects (409) 409
capecitabine (404) 404
analysis (401) 401
survival (399) 399
deoxycytidine - adverse effects (397) 397
tumors (395) 395
lung neoplasms - drug therapy (393) 393
fluorouracil - analogs & derivatives (366) 366
medicine & public health (364) 364
antineoplastic combined chemotherapy protocols - adverse effects (361) 361
gene expression (359) 359
drug synergism (357) 357
drug resistance, neoplasm (355) 355
aged, 80 and over (353) 353
antineoplastic agents - therapeutic use (351) 351
pancreatic neoplasms - metabolism (343) 343
hematology (338) 338
drug therapy (337) 337
tumor cells, cultured (337) 337
antineoplastic agents (336) 336
article (336) 336
mice, nude (334) 334
carcinoma, non-small-cell lung - drug therapy (329) 329
5-aza-2'-deoxycytidine (328) 328
carcinoma (327) 327
resistance (327) 327
antimitotic agents (322) 322
xenograft model antitumor assays (319) 319
adenocarcinoma - drug therapy (314) 314
cells (313) 313
metastasis (309) 309
cisplatin (308) 308
cancer therapies (304) 304
dna (301) 301
fluorouracil - administration & dosage (301) 301
kinases (292) 292
adenocarcinoma (291) 291
inhibition (291) 291
deoxycytidine - metabolism (290) 290
in-vitro (290) 290
cell survival - drug effects (289) 289
health aspects (287) 287
prognosis (287) 287
cell biology (285) 285
proteins (274) 274
azacitidine - analogs & derivatives (265) 265
cell lung-cancer (265) 265
genetic aspects (265) 265
methylation (265) 265
disease-free survival (261) 261
cell line (259) 259
cancer research (258) 258
antimetabolites, antineoplastic - administration & dosage (257) 257
mutation (257) 257
cisplatin - administration & dosage (256) 256
kinetics (254) 254
pancreatic neoplasms - genetics (254) 254
trial (249) 249
cell cycle (247) 247
combination (244) 244
drug resistance (242) 242
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4793) 4793
Chinese (15) 15
Japanese (10) 10
French (8) 8
German (6) 6
Russian (4) 4
Korean (3) 3
Czech (2) 2
Hungarian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 12/2010, Volume 335, Issue 3, pp. 830 - 840
Gemcitabine (2',2'-difluorodeoxycytidine), a deoxycytidine analog, and erlotinib, an epidermal growth factor receptor-tyrosine kinase inhibitor, are used... 
FACTOR RECEPTOR INHIBITORS | ACTIVATED PROTEIN-KINASE | EPIDERMAL-GROWTH-FACTOR | PANCREATIC-CANCER | PHASE-III | GENE-EXPRESSION | PHARMACOLOGY & PHARMACY | HOMOLOGOUS RECOMBINATION | MAMMALIAN-CELLS | RADIATION | GEFITINIB IRESSA | Erlotinib Hydrochloride | RNA, Small Interfering - genetics | Gene Expression - drug effects | Gene Expression - genetics | Humans | Ubiquitin - metabolism | Deoxycytidine - pharmacology | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - genetics | MAP Kinase Kinase 1 - genetics | Transfection | Antimetabolites, Antineoplastic - pharmacology | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | MAP Kinase Kinase 2 - genetics | Rad51 Recombinase - metabolism | Cell Survival - drug effects | MAP Kinase Kinase 1 - antagonists & inhibitors | Rad51 Recombinase - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | MAP Kinase Kinase 1 - metabolism | MAP Kinase Kinase 2 - metabolism | Down-Regulation - genetics | Drug Synergism | Drug Resistance, Neoplasm - genetics | Mitogen-Activated Protein Kinase 3 - metabolism | MAP Kinase Kinase 2 - antagonists & inhibitors | Cell Line, Tumor | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Proteasome Endopeptidase Complex - metabolism | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Mitogen-Activated Protein Kinase 1 - metabolism
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 9, pp. 2077 - 2085
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 04/2011, Volume 10, Issue 4, pp. 591 - 602
Checkpoint kinase 1 (CHK1) is an essential serine/threonine kinase that responds to DNA damage and stalled DNA replication. CHK1 is essential for maintenance... 
CANCER-CELLS | PHASE | ACTIVATION | DNA-DAMAGE CHECKPOINT | PRECLINICAL PHARMACOLOGY | ONCOLOGY | PHOSPHORYLATION | ABROGATION | CYCLIN-DEPENDENT KINASE | DISCOVERY | ATR | Protein Kinases - metabolism | Protein Kinases - genetics | Cyclin-Dependent Kinases - metabolism | Apoptosis - drug effects | DNA Replication - drug effects | Humans | Pyridinium Compounds - administration & dosage | Deoxycytidine - pharmacology | Immunoblotting | Pyrimidines - chemistry | Antimetabolites, Antineoplastic - administration & dosage | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | DNA Breaks, Double-Stranded - drug effects | RNA Interference | Antimetabolites, Antineoplastic - pharmacology | Molecular Structure | Cyclin-Dependent Kinases - genetics | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - pharmacology | Drug Screening Assays, Antitumor - methods | Pyrimidines - administration & dosage | Protein-Serine-Threonine Kinases - genetics | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Pyrimidines - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Pyridinium Compounds - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Pyrazoles - administration & dosage | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Checkpoint Kinase 2 | Checkpoint Kinase 1 | Mice | Protein Kinase Inhibitors - pharmacology | Histones - metabolism | Deoxycytidine - analogs & derivatives
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2016, Volume 22, Issue 8, pp. 851 - 860
Single-agent immunotherapy has achieved limited clinical benefit to date in patients with pancreatic ductal adenocarcinoma (PDAC). This may be a result of the... 
MEDICINE, RESEARCH & EXPERIMENTAL | SKIN WOUND REPAIR | DUCTAL ADENOCARCINOMA | DECREASES GROWTH | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUMOR-INFILTRATING MACROPHAGES | 2 KNOCKOUT MICE | ACTIN CYTOSKELETAL REARRANGEMENT | TISSUE STIFFNESS | CELL BIOLOGY | FAK | ANTIGEN RECEPTOR | T-CELLS | Immunohistochemistry | Pancreatic Neoplasms - metabolism | Humans | Carcinoma, Pancreatic Ductal - metabolism | Tumor Microenvironment | Deoxycytidine - pharmacology | Immunoblotting | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Immunotherapy | Antimetabolites, Antineoplastic - pharmacology | Carcinoma, Pancreatic Ductal - immunology | Disease Models, Animal | Tumor Escape - immunology | Immunotherapy, Adoptive - methods | Focal Adhesion Protein-Tyrosine Kinases - metabolism | Pancreatic Neoplasms - pathology | Reverse Transcriptase Polymerase Chain Reaction | Carcinoma, Pancreatic Ductal - pathology | Focal Adhesion Protein-Tyrosine Kinases - antagonists & inhibitors | Disease Progression | Animals | Aminopyridines - pharmacology | Pancreatic Neoplasms - immunology | Fibrosis | Cell Proliferation - drug effects | Mice | CD8-Positive T-Lymphocytes - immunology | Deoxycytidine - analogs & derivatives | Molecular targeted therapy | Care and treatment | Pancreatic cancer | Patient outcomes | Innovations | Genetic aspects | Properties | Phosphotransferases | Methods | Kinases | Cell adhesion & migration | pancreatic cancer | PDAC | CXCL12 | VS-4718 | immunotherapy | fibrosis | tumor microenvironment | PD-1
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 4/2016, Volume 113, Issue 15, pp. 4027 - 4032
Journal Article
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 1420 - 11
Masitinib, a highly selective protein kinase inhibitor, can sensitise gemcitabine-refractory cancer cell lines when used in combination with gemcitabine. Here... 
PHASE-III TRIAL | PLUS GEMCITABINE | THERAPY | HUMAN DEOXYCYTIDINE KINASE | INHIBITOR SELECTIVITY | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | CELL LINES | RESISTANCE | ADVANCED PANCREATIC-CANCER | SMALL-MOLECULE ACTIVATORS | Deoxycytidine Kinase - chemistry | A549 Cells | Phosphorylation | Imatinib Mesylate - pharmacology | Humans | Models, Molecular | Crystallography, X-Ray | Deoxycytidine - pharmacology | Drug Resistance, Neoplasm | Polypharmacology | Antineoplastic Agents - chemistry | Enzyme Activation - drug effects | Imatinib Mesylate - chemistry | Deoxycytidine Kinase - metabolism | Protein Kinase Inhibitors - chemistry | Models, Biological | Drug Design | Proteomics | Cell Line, Tumor | Thiazoles - chemistry | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Deoxycytidine - analogs & derivatives | Drugs | Imatinib | Target recognition | Gemcitabine | Toxicity | Activation | Pharmacology | Tumor cell lines | Protein kinase inhibitors | Drug resistance | Kinases | Chemical compounds | Modulators | Proteins | Deoxycytidine kinase | Protease inhibitors | Cell lines | Nucleosides | Nucleoside analogs | Cancer | Index Medicus | Cheminformatics | Biochemistry, Molecular Biology | Biophysics | Cristallography | Chemical Sciences | Life Sciences | Medicinal Chemistry | Organic chemistry | Medication | Biomolecules | Molecular Networks | Pharmaceutical sciences
Journal Article
Bioscience Reports, ISSN 0144-8463, 06/2008, Volume 28, Issue 3, pp. 161 - 176
Synopsis Axl is a receptor tyrosine kinase which promotes anti-apoptosis, mitogenesis, invasion, angiogenesis and metastasis, and is highly expressed in... 
CpG methylation | Axl receptor tyrosine kinase (RTK) | Transcription | 5-aza-2́- deoxycytidine (5-aza-dC) | Axl promoter | Specificity protein (Sp) | TRANSCRIPTION FACTORS | transcription | SP-FAMILY | CELL-GROWTH | ACTIVATOR PROTEIN-2-ALPHA-RELATED FACTOR | IDENTIFICATION | VASCULAR SMOOTH-MUSCLE | specificity protein (Sp) | CELL BIOLOGY | 5-aza-2 '-deoxycytidine (5-aza-dC) | GROWTH ARREST | PROTEIN-S | GAS6 | BINDING | Oncogene Proteins - genetics | Sp3 Transcription Factor - antagonists & inhibitors | Humans | Receptor Protein-Tyrosine Kinases - biosynthesis | HeLa Cells - metabolism | Promoter Regions, Genetic - genetics | Sp1 Transcription Factor - antagonists & inhibitors | RNA Interference | Oncogene Proteins - biosynthesis | Enzyme Induction - drug effects | Proto-Oncogene Proteins | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - genetics | Sp1 Transcription Factor - physiology | Cell Line, Tumor - metabolism | Gene Expression Regulation, Neoplastic - genetics | Genes, Reporter | Recombinant Fusion Proteins - biosynthesis | Mutagenesis, Site-Directed | Sp3 Transcription Factor - physiology | Neoplasm Proteins - biosynthesis | RNA, Small Interfering - pharmacology | Sp3 Transcription Factor - genetics | Azacitidine - analogs & derivatives | DNA Methylation - genetics | HeLa Cells - drug effects | Amino Acid Motifs | Azacitidine - pharmacology | Enzyme Induction - genetics | Receptor Protein-Tyrosine Kinases - genetics | Sp1 Transcription Factor - genetics | CpG Islands - genetics | Colorectal Neoplasms - pathology | DNA Methylation - drug effects | Index Medicus
Journal Article
Journal Article
Journal of Surgical Research, ISSN 0022-4804, 2014, Volume 187, Issue 1, pp. 6 - 13
Abstract Background When presenting with advanced stage disease, lung cancer patients have <5% 5-y survival. The overexpression of checkpoint kinase 1 (CHK1)... 
Surgery | Chemosensitivity | Radiosensitivity | CHK1 | NSCLC cell lines | AZD7762 | Combination therapies | SURVIVAL | SURGERY | STEM-CELLS | DNA-DAMAGE RESPONSE | ADENOCARCINOMA | TUMOR-CELLS | GEMCITABINE | CHK1 INHIBITION | TARGETED THERAPIES | CISPLATIN | Protein Kinases - metabolism | Carcinoma, Large Cell - drug therapy | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Thiophenes - therapeutic use | Protein Kinases - genetics | Guanine - analogs & derivatives | Humans | Lung Neoplasms - metabolism | Deoxycytidine - therapeutic use | Adenocarcinoma - metabolism | Urea - analogs & derivatives | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Guanine - therapeutic use | Lung Neoplasms - genetics | Cell Survival - drug effects | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Adenocarcinoma - drug therapy | Pemetrexed | Antimetabolites, Antineoplastic - therapeutic use | Drug Resistance, Neoplasm - genetics | Urea - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Checkpoint Kinase 1 | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Lung cancer, Small cell | Chemotherapy | Lung cancer, Non-small cell | Tumor proteins | Nuclear radiation | Cancer
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 08/2018, Volume 15, Issue 8, pp. 3260 - 3271
Journal Article